Cumulative incidence of relapse and death in patients treated with low-dose VenAza or ICH. (A) Death in remission occurred in 16.2% (VenAza) vs 27.2% (ICH) (P = .09). Death after relapse was comparable between groups. (B) At last follow-up, cumulative incidence of relapse was lower in the VenAza group (39.1%) than in ICH (89.4%; P = .006). Competing risks were analyzed using the Fine-Gray model implemented in the cmprsk package in R. Plots were generated with ggplot2, and no manual image processing was applied.